Interview with the Innovators

Managing Neuropathy That May Accompany ADC Therapy in Breast Cancer

How can clinicians monitor and manage neuropathy in patients with breast cancer receiving ADC therapy? In this video, Tajuana Bradley, MS, FNP-BC, and Abbey J. Kaler, MS, APRN, FNP-C, discuss practical approaches to initial and ongoing assessments, concomitant medication, and patient education on symptoms that should be reported promptly.

Watch Video Download Infographic

Featuring:

Tajuana Bradley, MS, FNP-BC
Nurse Practitioner
Georgia Cancer Specialists
Northside Hospital Cancer Institute
Lawrenceville, GA
Abbey J. Kaler, MS, APRN, FNP-C
University of Texas MD Anderson Cancer Center
Houston, TX

Managing Neuropathy That May Accompany ADC Therapy in Breast Cancer

Related Items

Managing Hematologic Toxicities With ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can clinicians monitor and manage hematologic toxicities in patients with breast cancer receiving ADC therapy? In this video, Tajuana Bradley, MS, FNP-BC, and Abbey J. Kaler, MS, APRN, FNP-C, discuss practical approaches to laboratory monitoring and the assessment and management of neutropenia, thrombocytopenia, and anemia, including toxicity grading, treatment modifications, and patient education on symptoms that should be reported promptly.
Assessing Patient Risk Before ADC Therapy in Breast Cancer
By Tajuana Bradley, MS, FNP-BC; Abbey J. Kaler, MS, APRN, FNP-C
Video Library
How can early identification of patient-specific risk factors help optimize patient outcomes and proactively manage toxicity with ADC therapy? In this video, Tajuana Bradley, DNP, FNP-BC, AOCNP, and Abbey Kaler, PA-C, discuss approaches to evaluating baseline risk factors, identifying patients who may be at increased risk for key ADC-related toxicities, and implementing monitoring, multidisciplinary care, and patient education strategies at treatment initiation.
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
By Jamie Carroll, APRN, CNP, MSN
Video Library
In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.
Journal of Oncology Navigation & Survivorship
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country